IEO and Politecnico di Milano have developed a “gut-on-chip” capable of predicting the response to immunotherapy in patients ...

Scientists reveal that the structure of gut bacteria-derived LPS determines whether cancer immunotherapy succeeds or fails—unlocking a new path to personalized treatments. Analysis: Gut ...

Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles.

A team of researchers from the European Institute of Oncology and the Politecnico di Milano, coordinated by Luigi Nezi, Team ...

Rutkowski and her team are actively investigating and hoping to develop ways for immune cells to ignore flagellin and enhance immunotherapy. The discovery of how flagellin inhibits ICI therapy is a ...

Discover a study that describes a host-intrinsic mechanism responsible for the failure of PD-L1 blockade in ovarian cancer.

Immunotherapy. 2012;4(6):629-647. In summary, M. tuberculosis is able to interfere with the host's immune response at multiple stages. However, there is one more aspect to consider that is highly ...

The update was delivered at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held 18-21 February ...

Immunotherapy. 2012;4(6):629-647. This review introduces the disease, particularly the complex interaction of M. tuberculosis with the host's immune system, as background to understanding the ...